Difference between revisions of "Part:BBa K3064010"
(→References) |
|||
| Line 3: | Line 3: | ||
<partinfo>BBa_K3064010 short</partinfo> | <partinfo>BBa_K3064010 short</partinfo> | ||
| − | It is a known type of E3 ubiquitin-protein ligase as an intracellular antibody effector in the antibody-mediated proteolysis pathway. | + | Trim 21 comes from the family of TRIM. ‘MMu’ means that it is from mouse. It is a known type of E3 ubiquitin-protein ligase as an intracellular antibody effector in the antibody-mediated proteolysis pathway. |
<!-- Add more about the biology of this part here --> | <!-- Add more about the biology of this part here --> | ||
Revision as of 07:56, 29 September 2019
mmuTrim21
Trim 21 comes from the family of TRIM. ‘MMu’ means that it is from mouse. It is a known type of E3 ubiquitin-protein ligase as an intracellular antibody effector in the antibody-mediated proteolysis pathway.
Usage and Biology
Trim 21 has a particular domain to recognize the Fc domain and combine with antibody marked no-enveloped virions. Using its E3 ubiquitin-protein ligase activity, trim 21 with the antibody bond to virons is degraded by the Ubiquitin dependent protease degradation pathway.
Due to the organism, therapeutic antibodies targeting disease-associated antigens in extracellular is a key tool for some certain diseases in current researches. Although some diseases is not caused by virons, trim 21 can be used in these diseased by blocking a particular pathogenic process.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BamHI site found at 75
Illegal BamHI site found at 778 - 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 176
- 1000COMPATIBLE WITH RFC[1000]
References
1.TRIM21[G/OL]. https://en.wikipedia.org/wiki/TRIM21 ,2019.
2.Stian Foss, Ruth Watkinson, Inger Sandlie, et al. TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity[J]. Immunological Reviews, 2015, 268(1):328-339.
3.Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity[J]. Rheumatology International, 2017, 37(8):1323-1333.